ID: h-8d124bccfe
Hypothesis
Enteric Nervous System Dysfunction as Self-Reinforcing Pathological Loop
PD patients exhibit dual ENS pathology: α-synuclein aggregation within enteric neurons and progressive loss of cholinergic/nitrergic neurons.
EvidencePending (0%)📖 0 cit🗣 3 debates✓ 12 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
PD patients exhibit dual ENS pathology: α-synuclein aggregation within enteric neurons and progressive loss of cholinergic/nitrergic neurons. This disrupts gut motility causing constipation, SIBO, and dysbiosis blooms (H. pylori, Klebsiella). Enteric glial reactivity and S100B release complete a feedforward inflammatory loop. Clinical observations are robust; the primary weakness is circular logic regarding initiating event. Gut-directed therapies (prokinetics, H. pylori eradication, FMT) may break this cycle.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["SNCA Alpha-Synuclein<br/>Presynaptic Protein"]
B["SNCA Misfolding<br/>Environmental Stress"]
C["SNCA Oligomers<br/>Toxic Protofibrils"]
D["Mitochondrial Pore<br/>Membrane Disruption"]
E["Lewy Body Formation<br/>Cytoplasmic Inclusions"]
F["Dopaminergic Neuron<br/>Dysfunction/Death"]
G["Nigrostriatal Degeneration<br/>Motor Symptoms"]
H["SNCA A53T/A30P/E46K<br/>Familial PD Mutations"]
A --> B
B --> C
C --> D
C --> E
D --> F
E --> F
F --> G
H -.->|"accelerates"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8⚖️ Evidence
⚖️ Evidence Matrix6 supports2 contradicts
Supports
Brain-First versus Gut-First Parkinson's Disease: A Hypothesis distinguishing two temporal trajectories.
2019PMID:31498132
Supports
Gut dysfunction in Parkinson's disease — ENS pathology present in >80% of PD patients, often preceding motor diagnosis.
2016PMID:27433087
Contradicts
Beyond α-synuclein transfer: pathology propagation — questions about directionality; may reflect cell-to-cell signaling rather than authentic templated misfolding.
2011PMID:22503115
Contradicts
Gut-first PD cases may not always develop brain pathology — variable penetrance; additional triggers required for self-reinforcing loop.
📖 Linked Papers (8)Export BibTeX ↗
The Body, the Brain, the Environment, and Parkinson's Disease.
Journal of Parkinson's disease (2024) · PubMed:38607765 ↗
No figures
Role of enteric glia and microbiota-gut-brain axis in parkinson disease pathogenesis.
Ageing Res Rev (2023) · PubMed:36455790 ↗
No figures
The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.
Nat Rev Neurol (2022) · PubMed:35750883 ↗
No figures
The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options.
Brain : a journal of neurology (2021) · PubMed:33856024 ↗
No figures
No figures
Prion-like propagation of α-synuclein in the gut-brain axis.
Brain research bulletin (2019) · PubMed:29894766 ↗
No figures
Brain-gut-microbiota axis in Parkinson's disease.
World journal of gastroenterology (2015) · PubMed:26457021 ↗
No figures
Gut microbiota are related to Parkinson's disease and clinical phenotype.
Mov Disord (2015) · PubMed:25476529 ↗
No figures
🏥 Translation
🧬 3D Protein Structure — SNCA
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for SNCA/GFAP/VIP/nNOS/CHAT from GTEx v10.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SNCA.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 1.0%
Volatility
Medium
0.0325
Events (7d)
3
Price History
▼15.8%💾 Resource Usage
API Calls
3
Total Cost
$0.0000
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF H. pylori eradication therapy (10-day bismuth-based quadruple therapy: bismuth 300mg QID, tetracycline 500mg QID, metronidazole 500mg TID, omeprazole 20mg BID) is administered to treatment-naïve ea | ≥5-point reduction in MDS-UPDRS Part III score at 12 months; ≥20% reduction in serum zonulin; ≥30% improvement in constipation severity ( Wexner constipation sc | — no observation — | pending | 0.38 |
| IF enteric glial S100B signaling is pharmacologically blocked (using anti-S100B neutralizing antibody or S100B siRNA) in an α-synuclein overexpression mouse model (Thy1-SNCA transgenic), THEN measurab | ≥30% reduction in p-S129 α-synuclein in myenteric plexus; ≥25% improvement in gut transit time; ≥40% reduction in fecal inflammatory cytokines (IL-6, TNF-α) | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF enteric glial S100B signaling is pharmacologically blocked (using anti-S100B neutralizing antibody or S100B siRNA) in an α-synuclein overexpression mouse model (Thy1-SNCA transgenic), THEN measurable reduction in enteric α-synuclein aggregation (≥30% decrease in p-S129 α-synuclein by western blot
Predicted outcome: ≥30% reduction in p-S129 α-synuclein in myenteric plexus; ≥25% improvement in gut transit time; ≥40% reduction in fecal inflammatory cytokines (IL-6,
Falsification: No significant reduction in enteric α-synuclein aggregation OR no improvement in gut motility after S100B blockade, indicating the feedforward inflammatory loop does not require glial S100B signaling
pendingconf 38%
IF H. pylori eradication therapy (10-day bismuth-based quadruple therapy: bismuth 300mg QID, tetracycline 500mg QID, metronidazole 500mg TID, omeprazole 20mg BID) is administered to treatment-naïve early-stage PD patients (Hoehn-Yahr 1-2, disease duration <3 years) with confirmed H. pylori infection
Predicted outcome: ≥5-point reduction in MDS-UPDRS Part III score at 12 months; ≥20% reduction in serum zonulin; ≥30% improvement in constipation severity ( Wexner const
Falsification: No significant difference in motor progression or gut permeability between H. pylori-eradicated and control groups at 12 months, indicating enteric pathogens do not contribute to PD progression via EN
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
1
Incoming
0
Outgoing
0
0 supporting
0 contradicting
1 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.